Understanding how SGLT2 inhibitors protect kidneys in type 2 diabetes
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how SGLT2 inhibitor medications (a type of diabetes drug) protect the kidneys in people with type 2 diabetes and chronic kidney disease. Researchers will use MRI scans to understand the protective effects, which could help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have type 2 diabetes and diabetic kidney disease (kidney damage caused by diabetes).
- Your kidneys must be working at least moderately well (a measure called eGFR should be above 30).
- You must have kidney disease that is considered moderate or severe risk of getting worse (based on kidney function and protein in urine).
- You must be taking an SGLT2 inhibitor (a common diabetes medicine like empagliflozin or dapagliflozin) for at least one year.
- You must be able to undergo an MRI scan (no pacemaker, not pregnant, no severe claustrophobia, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This study tests whether using a dual continuous glucose and ketone monitor can help people with type 1 diabetes safely take a class of drugs called SGLT2 inhibitors, which may improve blood sugar control but can increase the risk of diabetic ketoacidosis (DKA). By closely monitoring changes in glucose and ketone levels, the study aims to prevent dangerous episodes while benefiting from the drug's effects.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
Hear when a new Diabetic Kidney Disease (DKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.